Journal of Substance Abuse Treatment
Volume 37, Issue 3 , Pages 307-312 , October 2009

Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network

  • Hannah K. Knudsen, Ph.D.

      Affiliations

    • Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, 109 Medical Behavioral Science Building, Lexington, KY 40536-0086, USA
    • Corresponding Author InformationCorresponding author. Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, 109 Medical Behavioral Science Building, Lexington, KY 40536-0086, USA. Tel.: +1 859 323 3947; fax: +1 859 323 5350.
    • ,
  • Amanda J. Abraham, Ph.D.

      Affiliations

    • Institute for Behavioral Research, University of Georgia, 111A Barrow Hall, Athens, GA 30602-2401, USA
    • ,
  • J. Aaron Johnson, Ph.D.

      Affiliations

    • Institute for Behavioral Research, University of Georgia, 111A Barrow Hall, Athens, GA 30602-2401, USA
    • ,
  • Paul M. Roman, Ph.D.

      Affiliations

    • Institute for Behavioral Research, University of Georgia, 111A Barrow Hall, Athens, GA 30602-2401, USA
    • Department of Sociology, 119 Baldwin Hall, The University of Georgia, Athens, GA 30602-1611, USA

Received 22 September 2008 ,Revised 26 November 2008 ,Accepted 18 December 2008.

References 

  1. Allison PD. Logistic regression using the SAS System: Theory and application. Cary, NC: SAS Publishing; 1999;
  2. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, et al. Bringing buprenorphine–naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. American Journal on Addictions. 2004;13:S42–S46
  3. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. American Journal of Epidemiology. 2003;158:280–287
  4. Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, and Policy. 2008;3:17;(http://www.substanceabusepolicy.com/content/3/1/17)
  5. Ducharme LJ, Knudsen HK, Roman PM, Johnson JA. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment. 2007;32:321–329
  6. Ducharme LJ, Roman PM. Opioid treatment programs in the Clinical Trials Network: Representativeness and buprenorphine adoption. Journal of Substance Abuse Treatment. 2007;37:90–94
  7. Fennell ML, Warnecke RB. The diffusion of medical innovations. New York: Plenum; 1988;
  8. Hanson GR, Leshner AI, Tai B. Putting drug abuse research to use in real-life settings. Journal of Substance Abuse Treatment. 2002;23:69–70
  9. Knudsen HK, Ducharme LJ, Roman PM. Early buprenorphine adoption in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment. 2006;30:363–373
  10. Koch AL, Arfken CL, Schuster CR. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug and Alcohol Dependence. 2006;83:274–278
  11. Laliberte L, Fennell ML, Papandonatos G. The relationship of membership in research networks to compliance with treatment guidelines for early-stage breast cancer. Medical Care. 2005;43:471–479
  12. In:  Lamb S,  Greenlick MR,  McCarty D editor. Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment. Washington, DC: National Academy Press; 1998;p. 27–55
  13. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100:1090–1100
  14. McCarty D, Fuller B, Kaskutas LA, Wendt WW, Nunes EV, Miller M, et al. Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug and Alcohol Dependence. 2008;92:200–207
  15. Mee-Lee DL, Gartner L, Miller MM, Shulman GD, Wilford BB. Patient placement criteria for the treatment of substance-related disorders, second edition. Chevy Chase, MD: ASAM; 1996;
  16. National Institute on Drug Abuse . National Drug Abuse Treatment Clinical Trials Network. Available at: http://www.nida.nih.gov/CTN/protocol/brochure/2005_ctn_brochure%2010_17_05.pdfAccessed on August 28, 2008
  17. Oser CB, Roman PM. A categorical typology of naltrexone-adopting private substance abuse treatment centers. Journal of Substance Abuse Treatment. 2007;34:433–442
  18. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology. 1996;49:1373–1379
  19. Rogers EM. Diffusion of innovations. 5th ed.. New York: Free Press; 2003;
  20. Saxon AJ, McCarty D. Challenges in the adoption of new pharmacotherapies for addiction to alcohol and other drugs. Pharmacology & Therapeutics. 2005;108:119–128

PII: S0740-5472(08)00227-4

doi: 10.1016/j.jsat.2008.12.004

Journal of Substance Abuse Treatment
Volume 37, Issue 3 , Pages 307-312 , October 2009

Article Tools